It's more than two years since Elliot Goldstein, ex-SVP and director, worldwide strategic product development at SmithKline Beecham , became CEO of British Biotech PLC , whose credibility and share price had been reduced to tatters. A series of product setbacks, linked to the ousting of top executives, including research director Andy Millar, underlined management's failure to communicate realistically to investors. Once the bellwether of the young UK industry, British Biotech saw its market capitalization slide from a hyped and heady £2 billion down to £400 million in 1997, knocking the rest of the UK sector in the process.
But while Britain's biotech industry has long since picked itself up—policed by the BioIndustry Association's Code of Practice for communicating...




